866-997-4948(US-Canada Toll Free)

Dementia Associated with Alzimer’s Disease Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018-2026

Published By :

Transparency Market Research

Published Date : Dec 2018

Category :

Healthcare IT

No. of Pages : 172 Pages

Dementia Treatment Market - Overview

This report analyzes the current and future scenario of the global dementia associated with Alzheimer’s disease market for the period 2018 to 2026. Rise in geriatric population, increased prevalence of Alzheimer’s, high unmet medical needs, and rich pipeline are likely to be major drivers of the global dementia associated with Alzheimer’s disease market during the forecast period.

The dementia associated with Alzheimer’s disease market report comprises an elaborate executive summary, including a snapshot that provides information on various segments of the market. It also provides information and data analysis of the global market with respect to segments based on drug class, distribution channel, and region. A detailed qualitative analysis of drivers, restraints, and opportunities of the market has been provided in the market overview section. Additionally, the section comprises competitive matrix and profiles of key market players, along with business overview, to project the competitive landscape of the market. The section also provides market attractiveness analysis based on region and market share analysis in terms of key players, thereby presenting a thorough analysis of the overall competitive scenario in the dementia associated with Alzheimer’s disease market.

Dementia Associated with Alzheimer’s Disease Market: Key Segments

Based on drug class, the global dementia associated with Alzheimer’s disease market has been segmented into cholinergic/ cholinesterase (ChE) inhibitors, memantine, and combined drug (memantine & donepezil) and others. The segments have been analyzed based on available drugs used during the treatment of AD and cost-effectiveness. In terms of distribution channel, the global dementia associated with Alzheimer’s disease market has been divided into hospital pharmacies, retail, and online sales. Based on market size and forecast for each of these segments have been provided for the period 2018 to 2026, along with their respective CAGR for the forecast period 2016 to 2026, considering 2017 as the base year.

Dementia Associated with Alzheimer’s Disease Market: Regional Outlook

In terms of region, the global dementia associated with Alzheimer’s disease market has been segmented into five major regions: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa). Market size and forecast for each of these regions and the mentioned countries have been provided for the period 2018 to 2026, along with their respective CAGR for the forecast period 2016 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in the Report

The report also profiles major players operating in the global dementia associated with Alzheimer’s disease market based on various attributes, such as company overview, financial overview, product portfolio, business strategies, and recent developments. The players covered in the report include Merz Pharma GmbH & Co. KGaA., Novartis AG, Allergan plc. Pfizer, Inc., Daiichi Sankyo Company, Limited, Ono Pharmaceutical Co., Ltd, Johnson & Johnson Services, Inc., Eisai Co., Ltd., H. Lundbeck A/S, and  F. Hoffmann-La Roche Ltd.

The global dementia associated with Alzheimer’s disease market has been segmented as below:

  • Dementia Associated with Alzheimer’s Disease Market, by Drug Class
    • Cholinergic/ Cholinesterase (ChE) Inhibitors
    • Memantine
    • Combined Drug (Memantine & Donepezil) and Others
  • Dementia Associated with Alzheimer’s Disease Market, by Distribution Channel
    • Hospital Pharmacies
    • Retail
    • Online Sales
  • Dementia Associated with Alzheimer’s Disease Market, by Region
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia Pacific
      • India
      • China
      • Japan
      • Australia & New Zealand
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East & Africa
      • South Africa
      • GCC Countries
      • Rest of Middle East & Africa

Table of Content

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Dementia Associated with Alzheimer's Disease Market 

4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Dementia Associated with Alzheimer's Disease Market Analysis and Forecast, 2016–2026
4.4.1. Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Projections
4.5. Porter’s Five Force Analysis

5. Market Outlook
5.1. Disease Prevalence & Incidence Rate Globally with Key Countries
5.2. Pipeline Analysis

6. Global Dementia Associated with Alzheimer's disease Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Dementia Associated with Alzheimer's disease Market Value Forecast, by Drug Class, 2016–2026
6.3.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 
6.3.1.1. Donepezil 
6.3.1.2. Galantamine
6.3.1.3. Rivastigmine
6.3.2. Memantine 
6.3.3. Combined Drug (Memantine & Donepezil) and Others
6.4. Global Dementia Associated with Alzheimer's disease Market Attractiveness, by Drug Class

7. Global Dementia Associated with Alzheimer's disease Market Analysis and Forecast, by Distribution Channel 
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Dementia Associated with Alzheimer's Disease Market Value Forecast, by Distribution Channel, 2016–2026
7.3.1. Hospital Pharmacies
7.3.2. Retail 
7.3.3. Online Sales 
7.4. Global Dementia Associated with Alzheimer's Disease Market Attractiveness, by Distribution Channel 

8. Global Dementia Associated with Alzheimer's Disease Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Global Dementia Associated with Alzheimer's Disease Market Value Forecast, by Region
8.2.1. North America 
8.2.2. Europe 
8.2.3. Asia Pacific 
8.2.4. Latin America 
8.2.5. Middle East & Africa 
8.3. Global Dementia Associated with Alzheimer's Disease Market Attractiveness, by Country/Region

9. North America Dementia Associated with Alzheimer's Disease Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. North America Dementia Associated with Alzheimer's Disease Market Value Forecast, by Drug Class, 2016–2026
9.2.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 
9.2.1.1. Donepezil 
9.2.1.2. Galantamine
9.2.1.3. Rivastigmine
9.2.2. Memantine 
9.2.3. Combined Drug (Memantine & Donepezil) and Others
9.3. North America Dementia Associated with Alzheimer's Disease Market Value Forecast, by Distribution Channel, 2016–2026
9.3.1. Hospital Pharmacies
9.3.2. Retail 
9.3.3. Online Sales 
9.4. North America Dementia Associated with Alzheimer's Disease Market Value Forecast, by Country, 2016–2026
9.4.1. U.S.
9.4.2. Canada 
9.5. North America Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis 
9.5.1. By Drug Class
9.5.2. By Distribution Channel 
9.5.3. By Country

10. Europe Dementia Associated with Alzheimer's Disease Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Europe Dementia Associated with Alzheimer's Disease Market Value Forecast, by Drug Class, 2016–2026
10.2.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 
10.2.1.1. Donepezil 
10.2.1.2. Galantamine
10.2.1.3. Rivastigmine
10.2.2. Memantine 
10.2.3. Combined Drug (Memantine & Donepezil) and Others
10.3. Europe Dementia Associated with Alzheimer's Disease Market Value Forecast, by Distribution Channel, 2016–2026
10.3.1. Hospital Pharmacies
10.3.2. Retail 
10.3.3. Online Sales 
10.4. Europe Dementia Associated with Alzheimer's Disease Market Value Forecast, by Country/Sub-region, 2016–2026
10.4.1. Germany
10.4.2. France
10.4.3. U.K.
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Europe Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis 
10.5.1. By Drug Class
10.5.2. By Distribution Channel 
10.5.3. By Country/Sub-region

11. Asia Pacific Dementia Associated with Alzheimer's Disease Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Asia Pacific Dementia Associated with Alzheimer's Disease Market Value Forecast, by Drug Class, 2016–2026
11.2.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 
11.2.1.1. Donepezil 
11.2.1.2. Galantamine
11.2.1.3. Rivastigmine
11.2.2. Memantine 
11.2.3. Combined Drug (Memantine & Donepezil) and Others
11.3. Asia Pacific Dementia Associated with Alzheimer's Disease Market Value Forecast, by Distribution Channel, 2016–2026
11.3.1. Hospital Pharmacies
11.3.2. Retail 
11.3.3. Online Sales 
11.4. Asia Pacific Dementia Associated with Alzheimer's Disease Market Value Forecast, by Country/Sub-region, 2016–2026
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis 
11.5.1. By Drug Class
11.5.2. By Distribution Channel 
11.5.3. By Country/Sub-region

12. Latin America Dementia Associated with Alzheimer's Disease Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Latin America Dementia Associated with Alzheimer's Disease Market Value Forecast, by Drug Class, 2016–2026
12.2.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 
12.2.1.1. Donepezil 
12.2.1.2. Galantamine
12.2.1.3. Rivastigmine
12.2.2. Memantine 
12.2.3. Combined Drug (Memantine &Donepezil) and Others
12.3. Latin America Dementia Associated with Alzheimer's Disease Market Value Forecast, by Distribution Channel, 2016–2026
12.3.1. Hospital Pharmacies
12.3.2. Retail 
12.3.3. Online Sales 
12.4. Latin America Dementia Associated with Alzheimer's Disease Market Value Forecast, by Country/Sub-region, 2016–2026
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis 
12.5.1. By Drug Class
12.5.2. By Distribution Channel 
12.5.3. By Country/Sub-region

13. Middle East & Africa Dementia Associated with Alzheimer's Disease Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value Forecast, by Drug Class, 2016–2026
13.2.1. Cholinergic/ Cholinesterase (ChE) Inhibitors 
13.2.1.1. Donepezil 
13.2.1.2. Galantamine
13.2.1.3. Rivastigmine
13.2.2. Memantine 
13.2.3. Combined Drug (Memantine & Donepezil) and Others
13.3. Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value Forecast, by Distribution Channel, 2016–2026
13.3.1. Hospital Pharmacies
13.3.2. Retail 
13.3.3. Online Sales 
13.4. Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value Forecast, by Country/Sub-region, 2016–2026
13.4.1. GCC Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. Middle East & Africa Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis 
13.5.1. By Drug Class
13.5.2. By Distribution Channel 
13.5.3. By Country/Sub-region

14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis by Company (2016)
14.3. Market Footprint Analysis
14.3.1. By Region
14.3.2. By Drug Class Type
14.4. Competitive Business Strategies
14.5. Company Profiles
14.5.1. Merz Pharma GmbH & Co. KGaA 
14.5.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.1.2. Product Portfolio
14.5.1.3. SWOT Analysis
14.5.1.4. Financial Overview
14.5.1.5. Strategic Overview
14.5.2. Novartis AG  
14.5.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.2.2. Product Portfolio
14.5.2.3. SWOT Analysis
14.5.2.4. Financial Overview
14.5.2.5. Strategic Overview
14.5.3. Allergan plc.
14.5.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.3.2. Product Portfolio
14.5.3.3. SWOT Analysis
14.5.3.4. Financial Overview
14.5.3.5. Strategic Overview
14.5.4. Pfizer, Inc.  
14.5.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.4.2. Product Portfolio
14.5.4.3. SWOT Analysis
14.5.4.4. Financial Overview
14.5.4.5. Strategic Overview
14.5.5. Daiichi Sankyo Company, Limited  
14.5.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.5.2. Product Portfolio
14.5.5.3. SWOT Analysis
14.5.5.4. Financial Overview
14.5.5.5. Strategic Overview
14.5.6. Ono Pharmaceutical Co., Ltd. 
14.5.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.6.2. Product Portfolio
14.5.6.3. SWOT Analysis
14.5.6.4. Financial Overview
14.5.6.5. Strategic Overview
14.5.7. Johnson & Johnson Services, Inc. 
14.5.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.7.2. Product Portfolio
14.5.7.3. SWOT Analysis
14.5.7.4. Financial Overview
14.5.7.5. Strategic Overview
14.5.8. Eisai Co., Ltd. 
14.5.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.8.2. Product Portfolio
14.5.8.3. SWOT Analysis
14.5.8.4. Financial Overview
14.5.8.5. Strategic Overview
14.5.9. H. Lundbeck A/S 
14.5.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.9.2. Product Portfolio
14.5.9.3. SWOT Analysis
14.5.9.4. Financial Overview
14.5.9.5. Strategic Overview
14.5.10. F. Hoffmann-La Roche Ltd.  
14.5.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.5.10.2. Product Portfolio
14.5.10.3. SWOT Analysis
14.5.10.4. Financial Overview
14.5.10.5. Strategic Overvie

List of Table

Table 01: Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 02: Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Cholinergic/ Cholinesterase (ChE) Inhibitors, 2016–2026
Table 03: Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 04: Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 05: North America Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 06: North America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 07: North America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, (Cholinergic/ Cholinesterase (ChE) Inhibitors), 2016–2026
Table 08: North America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 09: Europe Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 10: Europe Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 11: Europe Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, (Cholinergic/ Cholinesterase (ChE) Inhibitors), 2016–2026
Table 12: Europe Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 13: Asia Pacific Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 14: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 15: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, (Cholinergic/ Cholinesterase (ChE) Inhibitors), 2016–2026
Table 16: Asia Pacific Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 17: Latin America Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 18: Latin America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 19: Latin America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, (Cholinergic/ Cholinesterase (ChE) Inhibitors), 2016–2026
Table 20: Latin America Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 21: Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 22: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 23: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Drug Class, (Cholinergic/ Cholinesterase (ChE) Inhibitors), 2016–2026
Table 24: Middle East & Africa Dementia Associated with Alzheimer’s Disease Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–202

List of Chart

Figure 01: Dementia Associated with Alzheimer's Disease Market Size (US$ Mn) and Distribution, by Region, 2018 and 2026
Figure 02: Dementia Associated with Alzheimer's Disease Market Value Forecast, by Drug Class, 2018(E)
Figure 03: Dementia Associated with Alzheimer's Disease Market Snapshot
Figure 04: Dementia Associated with Alzheimer's Disease Market Value Share
Figure 05: Dementia Associated with Alzheimer's Disease Market Value Share
Figure 06: Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast, 2016–2026
Figure 07: Global Dementia Associated with Alzheimer's Disease Market Value Share, by Drug Class, 2017
Figure 08: Global Dementia Associated with Alzheimer's Disease Market Value Share, by Distribution Channel, 2017
Figure 09: Global Dementia Associated with Alzheimer's Disease Market Value Share, by Region, 2017
Figure 10: Global Dementia Associated with Alzheimer's Disease Market Value Share Analysis, by Drug Class, 2018 and 2026
Figure 11: Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Cholinergic/ Cholinesterase (ChE)Inhibitor
Figure 12: Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Memantine
Figure 13: Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Combined Drug (Memantine & Donepezil) and Others
Figure 14: Global Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis, by Drug Class, 2018–2026
Figure 15: Global Dementia Associated with Alzheimer's Disease Market Value Share Analysis, by Distribution Channel, 2018 and 2026
Figure 16: Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies
Figure 17: Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail
Figure 18: Global Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Sales
Figure 19: Global Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis, by Distribution Channel
Figure 20: Global Dementia Associated with Alzheimer's Disease Market Value Share, by Region, 2018 and 2026
Figure 21: Global Dementia Associated with Alzheimer's Disease Market Attractiveness Analysis, by Region, 2018–2026
Figure 22: North America Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
Figure 23: North America Dementia Associated with Alzheimer's Disease Market Value Share, by Country, 2017 and 2026
Figure 24: North America Dementia Associated with Alzheimer's Disease Market Attractiveness, by Country, 2018–2026
Figure 25: North America Dementia Associated with Alzheimer's Disease Market Value Share, by Drug Class, 2017 and 2026
Figure 26: North America Dementia Associated with Alzheimer's Disease Market Attractiveness, by Drug Class, 2018–2026
Figure 27: North America Dementia Associated with Alzheimer's Disease Market Value Share, by Animal Type, 2017 and 2026
Figure 28: North America Dementia Associated with Alzheimer's Disease Market Attractiveness, by Animal Type, 2018–2026
Figure 29: Europe Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
Figure 30: Europe Dementia Associated with Alzheimer's Disease Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 31: Europe Dementia Associated with Alzheimer's Disease Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 32: Europe Dementia Associated with Alzheimer's Disease Market Value Share, by Drug Class, 2017 and 2026
Figure 33: Europe Dementia Associated with Alzheimer's Disease Market Attractiveness, by Drug Class, 2018–2026
Figure 34: Europe Dementia Associated with Alzheimer's Disease Market Value Share, by Distribution Channel, 2017 and 2026
Figure 35: Europe Dementia Associated with Alzheimer's Disease Market Attractiveness, by Distribution Channel, 2018–2026
Figure 36: Asia Pacific Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
Figure 37: Asia Pacific Dementia Associated with Alzheimer's Disease Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 38: Asia Pacific Dementia Associated with Alzheimer's Disease Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 39: Asia Pacific Dementia Associated with Alzheimer's Disease Market Value Share, by Drug Class, 2017 and 2026
Figure 40: Asia Pacific Dementia Associated with Alzheimer's Disease Market Attractiveness, by Drug Class, 2018–2026
Figure 41: Asia Pacific Dementia Associated with Alzheimer's Disease Market Value Share, by Distribution Channel, 2017 and 2026
Figure 42: Asia Pacific Dementia Associated with Alzheimer's Disease Market Attractiveness, by Distribution Channel, 2018–2026
Figure 43: Latin America Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
Figure 44: Latin America Dementia Associated with Alzheimer's Disease Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 45: Latin America Dementia Associated with Alzheimer's Disease Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 46: Latin America Dementia Associated with Alzheimer's Disease Market Value Share, by Drug Class, 2017 and 2026
Figure 47: Latin America Dementia Associated with Alzheimer's Disease Market Attractiveness, by Drug Class, 2018–2026
Figure 48: Latin America Dementia Associated with Alzheimer's Disease Market Value Share, by Animal Type, 2017 and 2026
Figure 49: Latin America Dementia Associated with Alzheimer's Disease Market Attractiveness, by Animal Type, 2018–2026
Figure 50: Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2016–2026
Figure 51: Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value Share, by Country/Sub-region, 2017 and 2026
Figure 52: Middle East & Africa Dementia Associated with Alzheimer's Disease Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 53: Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value Share, by Drug Class, 2017 and 2026
Figure 54: Middle East & Africa Dementia Associated with Alzheimer's Disease Market Attractiveness, by Drug Class, 2018–2026
Figure 55: Middle East & Africa Dementia Associated with Alzheimer's Disease Market Value Share, by Distribution Channel, 2017 and 2026
Figure 56: Middle East & Africa Dementia Associated with Alzheimer's Disease Market Attractiveness, by Distribution Channel, 2018–2026
Figure 57: Merz Pharma GmbH & Co. KGaA Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 58: Merz Pharma GmbH & Co. KGaA R&D Expenses, 2016–2017
Figure 59: Merz Pharma GmbH & Co. KGaA Breakdown of Net Sales, by Region, 2017
Figure 60: Merz Pharma GmbH & Co. KGaA Breakdown of Net Sales, by Business Segment, 2017
Figure 61: Novartis AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 62: Novartis AG R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 63: Novartis AG Breakdown of Net Sales, by Region, 2017
Figure 64: Novartis AG Breakdown of Net Sales, by Business Segment, 2017
Figure 65: Allergan plc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2017
Figure 66: Allergen plc. R&D Expenses, 2016–2017
Figure 67: Allergan plc. Sales and Marketing Expenses, 2017
Figure 68: Allergan plc. Breakdown of Net Sales, by Business Segment, 2017
Figure 69: Pfizer, Inc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2017
Figure 70: Pfizer, Inc. R&D Expenses and SI&A Expenses (%) 2015–2017
Figure 71: Pfizer, Inc. Breakdown of Net Sales, by Geography (Essential Health Segment), 2017
Figure 72: Pfizer, Inc. Breakdown of Net Sales, by Product (%), 2017
Figure 73: Daiichi Sankyo Company, Limited Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2017
Figure 74: Daiichi Sankyo Company, Limited R&D Expenses (US$ Bn), 2016–2017
Figure 75: Daiichi Sankyo Company, Limited Breakdown of Net Sales, by Region, 2017
Figure 76: Ono Pharmaceutical Co., Ltd. Research & Development Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2017
Figure 77: Ono Pharmaceutical Co., Ltd. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2017
Figure 78: Ono Pharmaceutical Co., Ltd. Breakdown of Net Sales, by Geography, 2017
Figure 79: Johnson & Johnson Services, Inc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
Figure 80: Johnson & Johnson Services, Inc. Pharmaceutical Products Segment Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
Figure 81: Johnson & Johnson Services, Inc. Breakdown of Net Sales, by Business Segment, 2017
Figure 82: Johnson & Johnson Services, Inc. Research & Development Cost, 2015 – 2017 (US$ Bn)
Figure 83: Eisai Co., Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
Figure 84: Eisai Co., Ltd. Breakdown of Net Sales, by Business 
Figure 85: H. Lundbeck A/S Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
Figure 86: H. Lundbeck A/S Breakdown of Net Sales, by Region, 2017
Figure 87: H. Lundbeck A/S Research & Development Cost, 2015 – 2017 (US$ Mn)
Figure 88: F. Hoffmann-La Roche Ltd. Breakdown of Net Sales, by Business Segment, 2017
Figure 89: F. Hoffmann-La Roche Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
Figure 90: F. Hoffmann-La Roche Ltd. Research & Development Cost, 2015 – 2017 (US$ Bn

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *